Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Myelodysplastic Syndromes
About this trial
This is an interventional treatment trial for Myelodysplastic Syndromes focused on measuring Higher-Risk, Retinoic Acid Receptor Alpha (RARA) positive, Newly Diagnosed, Myelodysplastic Syndromes
Eligibility Criteria
Key Inclusion Criteria:
- Participants must be at least 18 years old at the time of signing of an informed consent.
- Participants must be RARA-positive based on the investigational assay.
Participants must be newly diagnosed with HR-MDS as follows:
Diagnosis of MDS according to the World Health Organization (WHO) classification (Arber 2016) and classified by the Revised International Prognostic Scoring System (IPSS R) risk category as very high, high, or intermediate risk.
- Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.
Key Exclusion Criteria:
- Participants are suitable for and agree to undergo allogeneic HSCT at the time of Screening.
- Participants who received prior treatment for MDS with any hypomethylating agent, chemotherapy or allogeneic HSCT.
Sites / Locations
- University of ArizonaRecruiting
- UC IrvineRecruiting
- University of Southern CaliforniaRecruiting
- University of California, Los AngelasRecruiting
- Yale Cancer CenterRecruiting
- Cancer specialists of North FloridaRecruiting
- Comprehensive Hematology and OncologyRecruiting
- University of Illinois Cancer CenterRecruiting
- Orchard Healthcare Research Inc.Recruiting
- University of IowaRecruiting
- Tulane Cancer CenterRecruiting
- Johns Hopkins UniversityRecruiting
- American Oncology Partners of Maryland, PARecruiting
- SCL Health Research Institute, Inc. (St. Vincent Frontier Cancer Center)Recruiting
- Morristown Medical Center- Atlantic Hematology OncologyRecruiting
- Montefiore Medical Center & Albert Einstein College of MedicineRecruiting
- Northwell HealthRecruiting
- Novant Health IncRecruiting
- Novant Health Cancer Institute - ForsythRecruiting
- Wake Forest Baptist HealthRecruiting
- Cleveland ClinicRecruiting
- The Ohio State University Comprehensive Cancer CenterRecruiting
- Oregon Health and Science UniversityRecruiting
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterRecruiting
- University of Utah Huntsman Cancer InstituteRecruiting
- Medical University of GrazRecruiting
- Salzburg Cancer Research Institute (SCRI)Recruiting
- Klinik HietzingRecruiting
- ZNA MiddelheimRecruiting
- Institut Jules BordetRecruiting
- Hospital De JolimontRecruiting
- CHU de LiègeRecruiting
- AZ DeltaRecruiting
- CHU-UCL NamurRecruiting
- Juravinski Cancer CentreRecruiting
- London Health Sciences CenterRecruiting
- McGill University Health Centre (MUHC)Recruiting
- University Hospital OstravaRecruiting
- Nemocnice PelhrimovRecruiting
- General University Hospital PragueRecruiting
- CHU Amiens-PicardieRecruiting
- CHU d'AngersRecruiting
- Centre Hospitalier de la Côte Basque Hématologie CliniqueRecruiting
- Hôpital AvicenneRecruiting
- CHRU de BREST - Hôpital MorvanRecruiting
- CHU Clermont Ferrand / CHU EstaingRecruiting
- CHU Grenoble Alpes Hôpital Nord MichallonRecruiting
- Hopital MignotRecruiting
- CHU de LimogesRecruiting
- Centre Léon BérardRecruiting
- CHU Nantes - Hotel DieuRecruiting
- CHU de Nice - Hopital L'ArchetRecruiting
- Hôpital Saint LouisRecruiting
- Centre Hospitalier de PerpignanRecruiting
- CHU BordeauxRecruiting
- CHU Lyon SudRecruiting
- CHU PoitersRecruiting
- ICANS StrasbourgRecruiting
- Institut Gustave RoussyRecruiting
- Helios Klinikum Berlin Buch GmbHRecruiting
- Universitätsklinikum FreiburgRecruiting
- Universitätsklinikum Halle (Saale)Recruiting
- Universitätsklinikum MarburgRecruiting
- Universitätsklinikum MünsterRecruiting
- Semmelweis Egyetem
- Debrecen University Medical and Health Science CentreRecruiting
- Petz Aladar County Teaching HospitalRecruiting
- Josa Andras Teaching HospitalRecruiting
- Barzilai Medical Center of AshkelonRecruiting
- Bnai Zion Medical centerRecruiting
- Carmel Medical CenterRecruiting
- Shaare Zedek Medical CenterRecruiting
- Sheba Medical CenterRecruiting
- Kaplan Medical CenterRecruiting
- Tel Aviv Sourasky Medical CenterRecruiting
- IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruiting
- ASST Spedali Civili di BresciaRecruiting
- Azienda Ospedaliero-Universitaria di FerraraRecruiting
- AOU CareggiRecruiting
- Ospedale Policlinico San MartinoRecruiting
- Romagnolo Institute to Study Tumors "Dino Amadori "/ MeldonaRecruiting
- A.O.U. Maggiore della CaritàRecruiting
- Ospedale S.Maria delle CrociRecruiting
- Ospedale Infermi di RiminiRecruiting
- Ospedale S. Eugenio - ASL Roma 2Recruiting
- Fondazione Policlinico Tor VergataRecruiting
- AOUI di VeronaRecruiting
- University Clinic GdanskRecruiting
- Pomeranian Hospital GdyniaRecruiting
- Wojewodzki Szpital Specjalistyczny w LegnicyRecruiting
- University Clinic WarsawRecruiting
- H. Santa Creu i Sant PauRecruiting
- Fundación Privada Instituto de Investigación Oncológica Vall d'HebronRecruiting
- Hospital de la Santa Creu i Sant PauRecruiting
- Hospital Universitario de BurgosRecruiting
- Hospital San Pedro de AlcántaraRecruiting
- MD Anderson Cancer CenterRecruiting
- Hospital Universitario Fundacion Jimenez DiazRecruiting
- H. Universitario La PazRecruiting
- Hospital Universitario Central de AsturiaRecruiting
- Hospital Son LlatzerRecruiting
- Clinica Universidad NavarraRecruiting
- Hospital Universitario de SalamancaRecruiting
- Hospital Universitario Marqués de ValdecillaRecruiting
- Hospital Universitario Virgen Del RocioRecruiting
- Hospital Universitario y Politécnico La FeRecruiting
- Hospital Clinico Universitario de ValenciaRecruiting
- Western General Hospital in NHS Lothian Edinburgh ScotlandRecruiting
- Clatterbridge Cancer Centre NHS Foundation TrustRecruiting
- King's College Hospital NHS Foundation TrustRecruiting
- Sandwell and West Birmingham Hospital NHS TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Tamibarotene + Azacitidine
Tamibarotene Matched Placebo + Azacitidine
Tamibarotene: 6 mg administered orally twice per day (BID) on Days 8 through 28 of each 28-day treatment cycle. Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.
Placebo: Tamibarotene-matching tablets administered orally BID on Days 8 through 28 of each 28-day treatment cycle. Azacitidine: 75 mg/m^2 administered intravenously or subcutaneously each day on Days 1 through 7 of each 28-day treatment cycle.